BioSpace News Archive

Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of results from a phase 2a clinical trial of emixustat hydrochloride (emixustat) in patients with macular atrophy (MA) secondary to Stargardt disease (STGD) in the medical journal British Journal of Ophthalmology. The published arti

Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced Dr. Alex Lugovskoy has joined the Company as Chief Operating Officer, and that the Company has strengthened its Scientific Advisory Board with the addition of leading drug developer and clinician Dr. Rob Hershberg.

Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces fully optimized, high-affinity lead monoclonal antibodies (MAbs) against Claudin 18.2 (CLDN18.2), a structurally complex oncology target overexpressed on numerous solid tumors.

Kaleido Biosciences, Inc., announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30-December 3, 2020.

Paramit Corporation announced that it has acquired Emphysys, Inc., a leading technology development firm specializing in complex systems and products for the medical device, life sciences, and industrial equipment industries.

Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced today that it has signed an agreement to become a provider in the America’s Choice Provider Network (ACPN).

Vaxcyte, Inc. announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET.

Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in two upcoming virtual investor conferences:

The Board of Directors of BD has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercore’s 3rd Annual HealthCONx virtual conference at 11:20 a.m. ET on Thursday, December 3, 2020.